Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASA404 plus paclitaxel/carboplatin versus placebo plus paclitaxel/carboplatin in first-line advanced non-small cell lung cancer
NL-OMON32300Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing ASA404 + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Overall survival. Started Oct 2008; status: active, not recruiting.
02
Drugs
vadimezan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON32300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32300.